Independent · evidence-anchored—Reviewed by the GLPHelper Medical Team
EN·ES·For Providers ↗
glp·helper
Find a Provider →
glphelper.com/wegovy/texas/plano
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® Providers &
Prescriptions in Plano, TX

Verified Wegovy providers in Plano, TX. Checked against the NPI registry, sorted by waitlist — not by who pays us.[7]

city providers
9
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25–$1,150
monthly
§ 01Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults — same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose — the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9% — roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon — Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy
§ 02Clinical evidence
STEP 1–4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program — the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication — and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
§ 04Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%) — more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 05Cost & coverage — published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 – $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 – $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
—
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
—
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 – $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
§ 06Provider directory — Texas
5 of 5 shown

Find an Wegovy provider in Texas.

Every entry is checked against the NPI registry and the Texas medical board. Listings are ordered by current waitlist — the provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Texas city · /wegovy/texas/{city}
Houston
29.76°N
47 →
Dallas
32.78°N
38 →
Austin
30.27°N
31 →
San Antonio
29.42°N
28 →
Fort Worth
32.75°N
22 →
El Paso
31.76°N
11 →
Plano
33.02°N
9 →
Lubbock
33.58°N
7 →
Corpus Christi
27.80°N
6 →
Arlington
32.74°N
6 →
McAllen
26.20°N
5 →
Galveston
29.30°N
3 →
§ 07Frequently asked — Wegovy in Texas

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources — never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]